PDSB Stock — PDS Biotechnology Corp

PDS Biotechnology Corp (PDSB)

Updated October 16, 2026.

PDSB is a Stock. Total return is -99.5% over the past 11 years, 475.9 points behind SPY at 376.4%.

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies, with its lead product candidate PDS0101 currently in phase II trials for HPV-associated cancers and additional candidates in earlier stages targeting conditions including acute myeloid leukemia, prostate, breast, ovarian, colorectal, and lung cancers. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage oncology and immunotherapy development with higher risk tolerance for clinical and regulatory uncertainty.

PDSB performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.5% over the past 11 years, 475.9 points behind SPY at 376.4%. Over the past year its total return — price change plus distributions reinvested — is 19.5%. Its deepest 1-year drawdown was 85.9%.

PDSB key facts

Asset type

Stock

Asset class

Equity

Inception date

09/30/2015

Distribution frequency

None

Last close

$1.13 (as of 2026-10-16)

Market cap

$81,895,855

Average volume

6837412.0

Payment date

03/18/2019

Beta

1.168

Payout ratio

0.0%

EPS

$-0.57

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PDSB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.9%.

Who may consider PDSB — and who may not

It is a weaker fit for investors who need monthly cash flow (PDSB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PDSB

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions